The DNA Diagnostics Market is poised for growth due to increasing chronic and infectious diseases. Opportunities lie in next-generation sequencing advancements and oncology diagnostics, driven by ...

Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and ...

Metabolic diseases such as obesity, fatty liver, and insulin resistance are rapidly increasing worldwide, but fundamental ...

Qiagen is a consumable molecular diagnostics and life-science tools platform and offers QuantiFERON, QIAstat-Dx, QIAcuity ...

Lucid's Q3 2025 showed 2,841 tests and $7.1 million in pro forma revenues billed, but only $1.2 million could be ...

Opportunities in the Next Generation Cancer Diagnostics Market include leveraging advancements in genomic and proteomic ...

With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.

Spanish cancer biomarker medtech Reveal Genomics has boosted the roles of three of its founding members. | Spanish cancer biomarker medtech Reveal Genomics has boosted the roles of three of its ...

The MarketWatch News Department was not involved in the creation of this content.-- The company appoints Joel Parker, Ph.D., as Chief Scientific Officer; Ana Vivancos, Ph.D., as D ...

The global liquid biopsy market is experiencing substantial growth, driven by increasing demand for non-invasive diagnostic technologies that detect molecular biomarkers using liquid samples, thus ...

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's ...

The market for breast cancer liquid biopsy testing devices offers significant opportunities driven by rising breast cancer incidence and demand for non-invasive, frequent genomic profiling solutions.